February 19, 2016
The Food and Drug Administration (FDA) has approved Briviact (brivaracetam) as an add-on treatment to other medications for the treatment of partial onset seizures in patients with epilepsy aged ≥16 years. Patients with epilepsy will often have recurring seizures that cause a variety of symptoms, including abnormal thinking and behavior, as well as abnormal sensations and/or uncontrolled movements or spasms.
Brivaracetam’s effectiveness was examined in 3 clinical trials involving 1550 participants. When taken with other medications brivaracetam proved to be effective in reducing the frequency of seizures. The most common side effects reported were dizziness, drowsiness, fatigue, nausea, and vomiting.
According to the FDA, brivaracetam must be dispensed with a Medication Guide for patients. This guide provides important information about the medication’s use and risks.
Briviact is marketed by UCB, Inc.—Alessia D'Anna